Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapyHannah Lust, Rawan Faramand, Liora M. Schultz et al.|Blood Advances|2025Cited by 15
Information standards for innovative surgery: what patients need to knowChristin Hoffmann, Malini Mistry, Barry Main et al.|British journal of surgery|2025Cited by 4
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemiaYannis K. Valtis, Jae H. Park, Chenyu Lin et al.|Blood Advances|2025Cited by 3
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real worldAaron C. Logan, Razan Mohty, Fevzi Yalniz et al.|Blood|2025Cited by 2
Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaNoam E. Kopmar, Katherine C. Sutherland, Ted Gooley et al.|Blood Immunology & Cellular Therapy|2025Cited by 1